Valuation
- Market cap
- 2,373,780,000
- Revenue TTM
- $6,940,000
- Net income TTM
- $-212,390,000
- PE ratio
- 0.00
- Forward PE
- —
- Profit margin
- -3,060.37%
- Debt to equity
- 0.00
Trading
- Volume
- 1,171,600
- Avg volume
- 1,182,834
- Day's range
- $20.82 – $21.46
- Shares out
- 113,578,000
- Stochastic %K
- 4%
- Beta
- 2.55
- Analysts
- Strong Sell
- Price target
- $35.20
Company profile
Immunome, Inc., a biotechnology company, engages in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics in the United States. The company develops clinical asset comprising Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and IM-1021, a receptor tyrosine kinase-like orphan r...
Show more
Immunome, Inc., a biotechnology company, engages in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics in the United States. The company develops clinical asset comprising Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and IM-1021, a receptor tyrosine kinase-like orphan receptor 1 antibody-drug conjugate (ADC), which is in Phase 1 clinical trial. It is also developing preclinical assets, including IM-3050, a fibroblast activation protein targeted radioligand therapy; and solid tumor ADC drug candidates, such as IM-1617, IM-1340, and IM-1335. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.
- Industry
- Biotechnology
- Sector
- Healthcare
- Phone
- 425 939 7410
- Website
- https://immunome.com
- Address
- 18702 North Creek Parkway, Suite 100, Bothell, United States
Latest news
No headlines yet.
